rAAV CSF Delivery for Brain Disease Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods struggle to effectively deliver therapeutic agents to the central nervous system (CNS) due to the blood-brain barrier, limiting treatments for diseases such as lysosomal storage diseases and neurodegenerative disorders.
Innovation Solution
Administering an rAAV particle comprising an AAV capsid protein and a vector with a nucleic acid encoding a therapeutic agent to the cisterna magna, allowing cells that contact cerebrospinal fluid to express the therapeutic agent, thereby treating diseases like lysosomal storage diseases and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are delivered intravenously to treat CNS diseases, then the treatment can reach systemic circulation, but the agents cannot cross the blood-brain barrier to reach the central nervous system
Solution Approach 1:
The patent uses cerebrospinal fluid (CSF) as an intermediary medium to deliver therapeutic agents to the CNS. By injecting rAAV particles into the cisterna magna, the therapy utilizes the CSF circulation pathway to distribute the therapeutic agent throughout the ventricular system and reach target cells in the CNS, bypassing the blood-brain barrier obstruction
Solution Approach 2:
The patent extracts the therapeutic agent delivery from the systemic circulation pathway and redirects it through the CSF pathway. By removing the constraint of intravenous administration and using intracisternal injection, the therapy bypasses the blood-brain barrier and directly accesses the CNS through the subarachnoid space
2Reliability
If therapeutic agents are delivered directly to the brain, then the agents can reach the CNS, but the distribution is not widespread throughout the central nervous system
Solution Approach 1:
The patent employs the CSF circulation system as a universal delivery network that naturally distributes therapeutic agents to multiple regions of the CNS simultaneously. The rAAV particles injected into the cisterna magna are carried by CSF flow to reach the ventricular system, subarachnoid space, and various brain regions, providing widespread distribution through a single injection site
Solution Approach 2:
The patent utilizes the hydrodynamic flow of cerebrospinal fluid to distribute therapeutic agents throughout the CNS. The natural circulation and convection currents of CSF act as a fluid transport system, carrying the rAAV particles from the injection site through the ventricular system and into the subarachnoid space, achieving widespread distribution without mechanical intervention
3Ease of operation
If conventional gene therapy methods are used to target CNS diseases, then the treatment approach is simple, but the methods fail to achieve effective gene transfer to CNS cells
Solution Approach 1:
The patent introduces recombinant adeno-associated virus (rAAV) particles as a viral vector intermediary to facilitate efficient gene transfer to CNS cells. The rAAV particles serve as a mediator that can infect and transduce CNS cells, including ependymal cells and other cells in contact with CSF, achieving reliable gene transfer while maintaining relatively simple administration through intracisternal injection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves significant distribution and expression of therapeutic agents within the CNS, delaying disease onset and progression, and in some cases, doubling the life span of affected animals.
Implementation Method 1
administering to the mammal's cisterna magna an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic agent inserted between a pair of AAV inverted terminal repeats in a manner effective to infect cells that contact the cerebrospinal fluid (CSF)
Data Source
AI summary
The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.